Neutral Rating for AbbVie Amid Revenue Challenges and Limited Upside Potential
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...
Reuters14d
Abbvie Inc
US FDA approves expanded use of Lilly's bowel disease drug Healthcare & Pharmaceuticalscategory· January 16, 2025 AbbVie plans to "commit less capital" towards experimental medicines for ...
AbbVie price target lowered to $205 from $215 at Citi
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...